Drug Profile


Alternative Names: HMed-IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinase

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hansa Medical AB
  • Developer Hansa Medical AB; Linkoping University; University College London
  • Class Antibacterials; Antirheumatics; Bacterial proteins; Enzymes
  • Mechanism of Action Immunoglobulin modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Thrombotic thrombocytopenic purpura; Transplant rejection
  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 02 Aug 2017 Pooled efficacy and safety analysis from three phase II trials in Transplant rejection (Prevention) released by Hansa Medical
  • 20 Jul 2017 Preclinical trials in Cancer in Sweden, before July 2017
  • 19 May 2017 Ides receives Priority Medicine (PRIME) status for Transplant rejection in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top